New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting injectable formulation of risperidone microspheres Additional UZEDY...
United States Pharmacokinetic Pop Eric Hughes Drug Administration Teva Pharmaceuticals Population Pharmacokinetic Modeling Following Administration Of Olanzapine
Source: marketscreener.com